FDA panel unanimously votes to recommend GSK shingles vaccine

(Reuters) – A U.S. Food and Drug Administration advisory panel on Wednesday voted 11-0 that the safety and efficacy of GlaxoSmithKline’s shingles vaccine warrants approval for its use in adults aged 50 and over.

Panel members said Shingrix represents an improvement over Zostavax, the current marketed shingles prevention vaccine from Merck & Co.

While the FDA is not required to follow the advice of its expert panels, it typically does so, with an approval decision expected in coming weeks.

Reporting by Bill Berkrot; editing by Grant McCool

Our Standards:The Thomson Reuters Trust Principles.

Leave a Reply

Your email address will not be published. Required fields are marked *